Enrolling by invitation NCT07435207
Thrombotic RIsk FActors in AL-goneurodystrophy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Algoneurodystrophy. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The primary objective of the study is to evaluate the prevalence of blood prothrombotic factors in CRPS patients and their role in predicting response to neridronic acid treatment.
Primary outcome measures
- Pain VAS [Time frame: 1,3 and 6 months after therapy]
Eligibility criteria
Inclusion Criteria:Clinical (according to Budapest clinical diagnostic criteria for CRPS)
- patients aged 18 years or more
Exclusion Criteria:patients unable to give consent
\-
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
Italy · 1 center
- Fondazione IRCCS Policlinico San Matteo di Pavia — Pavia
Identifiers
NCT: NCT07435207 · TRIF-AL